SS-31 vs Epitalon.

SS-31, known generically as elamipretide and chemically as the tetrapeptide D-Arg-Dmt-Lys-Phe-NH₂ (Dmt = 2',6'-dimethyltyrosine), is a synthetic, cell-permeable, mitochondria-targeting peptide of the "Szeto-Schiller" (SS) aromatic-cationic class, originally discovered by Hazel Szeto and Peter Schiller at Cornell during opioid-peptide work. It is the lead clinical candidate of this class and, as elamipretide HCl, received its first regulatory approval in 2025. It is best understood as a mitochondrial protective/bioenergetic agent rather than a growth-factor or "anabolic" peptide.

Epitalon (also spelled Epithalon or Epithalone; sequence Ala-Glu-Asp-Gly, abbreviated AEDG) is a synthetic tetrapeptide developed in the 1980s by the Russian gerontologist Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It was designed to reproduce the proposed active fragment of Epithalamin, a crude peptide extract of the bovine pineal gland, and is classified as a short "peptide bioregulator." It is not a small-molecule drug or a hormone; the corresponding AEDG sequence was reported to be detectable in physiological pineal tissue only in 2017.

SS-31 carries an alternating aromatic-cationic motif giving it a net positive charge that drives selective, concentration-dependent accumulation (reported >1000-fold over cytosol) in the inner mitochondrial membrane, where it binds reversibly to cardiolipin, an anionic phospholipid unique to that membrane. By associating with cardiolipin it is thought to stabilize cristae architecture, protect the cardiolipin-cytochrome c interaction and electron-transport-chain organization, support membrane potential and ATP synthesis, and reduce mitochondrial reactive oxygen species. Unlike a classic free-radical scavenger, current biophysical work (e.g., studies of its effect on bilayer surface electrostatics) frames its primary action as modulation of mitochondrial membrane structure/electrostatics rather than simple antioxidant chemistry. These mechanisms are well characterized in cell and tissue models; the downstream clinical consequences in humans remain only partially established.

The most cited proposed mechanism is activation of telomerase: in cultured human somatic cells, Epitalon has been reported to induce telomerase reverse transcriptase expression, lengthen telomeres, and extend the number of cell divisions past normal replicative (Hayflick) limits. A second proposed mechanism is epigenetic/gene-regulatory: AEDG is a short, cell-penetrating peptide that is hypothesized to bind directly to specific DNA promoter regions and modulate transcription, with reported effects on melatonin-synthesis enzymes (e.g., AANAT), interleukin-2, and neuronal differentiation genes. It has also been described as modulating pineal melatonin output and as having antioxidant effects in animal and Drosophila models. Importantly, after roughly 25 years of research the authoritative 2025 review concludes the true mechanism of action remains unclear, and some findings (e.g., on melatonin secretion) directly conflict between studies.

The strongest human evidence is in Barth syndrome: based largely on the TAZPOWER program (an improvement in knee-extensor muscle strength taken as reasonably likely to predict clinical benefit), the FDA granted accelerated approval to elamipretide HCl (brand FORZINITY, Stealth BioTherapeutics) in September 2025 for Barth syndrome in patients weighing at least 30 kg, the first approved mitochondria-targeted peptide. In contrast, the larger Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy (Karaa et al., Neurology 2023, ~218 participants) FAILED its co-primary endpoints (6-minute walk test and Total Fatigue Score), though post hoc analyses suggested possible benefit in a mitochondrial-DNA replisome/maintenance subgroup, motivating the follow-up NuPOWER trial. Trials in heart failure (PROGRESS-HF) and dry age-related macular degeneration (ReCLAIM) likewise missed their primary endpoints. Most other indications (kidney injury, aging, Barth cardiac and broader neurodegeneration) rest on preclinical/animal data, so the human evidence base is narrow and, outside Barth syndrome, largely negative or unproven.

Most evidence is preclinical (cell culture, Drosophila, mice, and rats), where Epitalon and Epithalamin have shown telomere lengthening and antioxidant effects; in some rodent lifespan experiments from Khavinson's group, they also reduced tumor incidence and extended mean lifespan. Human data are far thinner and come almost entirely from the same Russian research network. The most-cited human report (Khavinson & Morozov, Neuro Endocrinol Lett 2003, PMID 14523363) describes a 6–8 year follow-up of 266 elderly subjects in which Epithalamin (the pineal extract, not synthetic Epitalon) and thymalin were associated with reduced mortality versus controls; a related 15-year follow-up was published in 2011 (PMID 22451889). There are also small open-label reports in retinitis pigmentosa and a circadian/melatonin study. These studies are open-label, often unblinded, frequently use the crude extract rather than the synthetic tetrapeptide, and have not been independently replicated by Western randomized controlled trials. The human-vs-preclinical gap is large and unresolved.

Across clinical trials the most commonly reported adverse events have been injection-site reactions (pain, redness, swelling) consistent with subcutaneous administration, with milder reports of headache, dizziness, and nausea; published trial data generally did not show clinically significant changes in vital signs, routine labs, or ECG over extended dosing. However, long-term safety beyond the studied trial populations, and safety of non-pharmaceutical "research-use" material sold outside the approved product, are not established. Because the only rigorously studied, quality-controlled form is the FDA-approved prescription product, gray-market SS-31 carries additional unknowns around purity, sterility, and identity. This summary describes documented findings only and intentionally excludes any dosing or administration details.

No rigorous, modern toxicology package exists for Epitalon. The 2025 International Journal of Molecular Sciences review explicitly states that data on this peptide's short- and long-term toxicity, genotoxicity, carcinogenic potential, and drug interactions are missing, and that these would be required before it could be approved as a pharmaceutical ingredient outside Russia. A specific theoretical concern is that a telomerase-activating compound could in principle promote survival or proliferation of abnormal cells, so its long-term oncologic safety in humans is genuinely unknown. Material sold for "research" use is unregulated, with no assurance of identity, purity, sterility, or endotoxin control. There are essentially no controlled human safety trials by Western standards.

As elamipretide HCl (FORZINITY), SS-31 received FDA accelerated approval in September 2025 for Barth syndrome, making it the first approved mitochondria-targeted peptide; accelerated approval means continued approval may depend on confirmatory benefit. For all other uses (e.g., heart failure, mitochondrial myopathy, ophthalmic and "anti-aging" applications) it remains investigational or unproven, and material marketed as "SS-31" for research is not an FDA-approved drug for those purposes.

Epitalon/Epithalamin reached clinical use only in Russia and has never been approved by the FDA or EMA; it is not an approved drug or dietary supplement in the United States and is sold there only as a research-use-only chemical. It is not a WADA-prohibited substance by name, though peptide-based agents can fall under broader anti-doping categories.